---
title: "Annovis Bio, Inc. (ANVS.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/ANVS.US.md"
symbol: "ANVS.US"
name: "Annovis Bio, Inc."
industry: "Biotechnology"
datetime: "2026-06-10T02:29:06.990Z"
locales:
  - [en](https://longbridge.com/en/quote/ANVS.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/ANVS.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/ANVS.US.md)
---

# Annovis Bio, Inc. (ANVS.US)

## Company Overview

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company’s lead product candidate is Buntanetap, which is in phase 3 to treat alzheimer’s disease, as well as in open-label phase 3 to treat parkinson’s disease. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer’s disease and dementia. Annovis Bio, Inc.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [www.annovisbio.com](https://www.annovisbio.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: 
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 1970-01-01T00:00:00.000Z

**Overall:  (0.00)**

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -2.61 | 282 | - | - | - |
| PB | 4.47 | 316 | 6.12 | 3.82 | 2.29 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-27T04:00:00.000Z

Total Analysts: **2**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 1 | 50% |
| Overweight | 1 | 50% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 1.77 |
| Highest Target | 17.00 |
| Lowest Target | 8.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/ANVS.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/ANVS.US/norm.md)
- [Related News](https://longbridge.com/en/quote/ANVS.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/ANVS.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**